,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,880,2,1,,26752306,2119,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
1,880,2,1,,26752306,2119,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
2,1030,2,1,,26752306,2119,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
3,1332,1,1,,49698847,2119,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
4,1457,1,1,,26752306,2119,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
5,1458,1,1,,26752306,2119,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
6,1460,1,3,,26752306,2119,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
7,1463,1,1,,26752306,2119,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
8,1468,1,1,,26752306,2119,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
9,1469,1,1,,26752306,2119,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
10,1469,1,1,,50105226,2119,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
11,1471,2,1,,26752306,2119,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
12,1477,1,1,,26752306,2119,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
13,1477,1,1,,50105226,2119,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
14,1479,1,2,,26752306,2119,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
15,1479,1,2,,50105226,2119,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
16,1487,1,1,,26752306,2119,Inconclusive,27436948.0,4000.0,15.8489,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
17,1490,2,1,,26752306,2119,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
18,1490,2,1,,50105226,2119,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
19,1688,1,1,,26752306,2119,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
20,1766,1,1,,26752306,2119,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
21,1766,1,1,,26752306,2119,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
22,1766,1,1,,50105226,2119,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
23,1766,1,1,,50105226,2119,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
24,1768,1,1,,26752306,2119,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
25,1768,1,1,,26752306,2119,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
26,1768,1,1,,50105226,2119,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
27,1768,1,1,,50105226,2119,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
28,1865,1,1,,26752306,2119,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
29,2062,1,2,,85209662,2119,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
30,2101,1,1,,26752306,2119,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
31,2101,1,1,,50105226,2119,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
32,2107,1,1,,26752306,2119,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
33,2107,1,1,,50105226,2119,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
34,2112,1,1,,26752306,2119,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
35,2112,1,1,,50105226,2119,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
36,2240,1,1,,85788463,2119,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
37,2241,1,1,,85788463,2119,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
38,2275,1,1,,85788463,2119,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
39,2313,1,1,,85788463,2119,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
40,2322,1,1,,85788463,2119,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
41,2330,1,1,,85788463,2119,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
42,2451,1,2,,50105226,2119,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
43,2472,1,2,,50105226,2119,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
44,2517,2,1,,26752306,2119,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
45,2517,2,1,,50105226,2119,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
46,2528,1,2,,26752306,2119,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
47,2528,1,2,,50105226,2119,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
48,2546,1,1,,26752306,2119,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
49,2546,1,1,,50105226,2119,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
50,2549,1,1,,26752306,2119,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
51,2549,1,1,,50105226,2119,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
52,2551,1,1,,26752306,2119,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
53,2551,1,1,,50105226,2119,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
54,2660,1,1,,90340777,2119,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
55,2666,1,1,,90340777,2119,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
56,2667,1,1,,90340777,2119,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
57,2668,1,1,,90340777,2119,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
58,4411,5,1,,103164453,2119,Active,,,0.11749000000000001,Ki,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,Confirmatory,8568799.0,
59,7783,3,4,,103164453,2119,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
60,8002,5,2,,103164453,2119,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
61,15120,3,3,,103164453,2119,Unspecified,,,,,Percent of the drug absorbed after administration to humans was determined,Other,10346926.0,
62,18847,3,4,,103164453,2119,Unspecified,,,,,Percent of drug absorbed by human intestine after oral administration,Other,11020286.0,
63,19006,4,3,,103164453,2119,Unspecified,,,,,Calculated membrane partition coefficient (Kmemb),Other,15027870.0,
64,19419,3,4,,103164453,2119,Unspecified,,,,,Partition coefficient (logD7.4),Other,9544199.0,
65,19424,3,4,,103164453,2119,Unspecified,,,,,Partition coefficient (logD7.4),Other,11448232.0,
66,20050,3,3,,103164453,2119,Unspecified,,,,,Human absorption A (%),Other,9544199.0,
67,21254,3,4,,103164453,2119,Unspecified,,,,,Mono layer permeability of human intestinal Caco-2 cells,Other,9876108.0,
68,23672,3,3,,103164453,2119,Unspecified,,,,,Partition coefficient (logP),Other,7381857.0,
69,25572,3,4,,103164453,2119,Unspecified,,,,,Dissociation constant of the compound,Other,9876108.0,
70,25870,3,3,,103164453,2119,Unspecified,,,,,Tested for the dissociation constant of the compound,Other,7381857.0,
71,26362,4,3,,103164453,2119,Unspecified,,,,,Ionization constant (pKa),Other,14971904.0,
72,26525,3,4,,103164453,2119,Unspecified,,,,,Distribution coefficient measured in Octanol/buffer (0.15 M KCl),Other,9876108.0,
73,27167,3,4,,103164453,2119,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
74,28233,3,3,,103164453,2119,Unspecified,,,,,Fraction ionized (pH 7.4),Other,12061889.0,
75,28234,3,4,,103164453,2119,Unspecified,,,,,% absorbed in human GI-tract,Other,11300874.0,
76,28235,3,3,,103164453,2119,Unspecified,,,,,Unbound fraction (plasma),Other,12061889.0,
77,28236,3,3,,103164453,2119,Unspecified,,,,,Unbound fraction (tissues),Other,12061889.0,
78,28392,3,3,,103164453,2119,Unspecified,,,,,Apparent permeability coefficient (Papp) (Caco-2 cell monolayer),Other,11384238.0,
79,28399,3,3,,103164453,2119,Unspecified,,,,,Cellular permeability (Pc) (Caco-2 cell monolayer),Other,11384238.0,
80,28679,3,4,,103164453,2119,Unspecified,,,,,Partition coefficient (logD6.8),Other,11300874.0,
81,28681,3,4,,103164453,2119,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
82,28921,3,3,,103164453,2119,Unspecified,,,,,Partition coefficient (logP) (hexadecane),Other,11300874.0,
83,28924,3,3,,103164453,2119,Unspecified,,,,,Effective permeability (Pe) across a hexadecane membrane (pH 6.8),Other,11300874.0,
84,28925,3,3,,103164453,2119,Unspecified,,,,,Highest effective permeability across hexadecane membrane (pH 4-8),Other,11300874.0,
85,28926,3,3,,103164453,2119,Unspecified,,,,,Effective permeability corrected for ionization,Other,11300874.0,
86,28928,3,3,,103164453,2119,Unspecified,,,,,Intrinsic permeability of the compound,Other,11300874.0,
87,29337,3,3,,103164453,2119,Unspecified,,,,,Ionisation constant (pKa),Other,12061889.0,
88,29359,3,3,,103164453,2119,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
89,29423,3,4,,103164453,2119,Unspecified,,,,,HPLC capacity factor (k'),Other,12061889.0,
90,29811,4,3,,103164453,2119,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
91,29844,3,3,,103164453,2119,Unspecified,,,,,Fraction absorbed after oral administration in humans,Other,11384238.0,
92,29845,3,4,,103164453,2119,Unspecified,,,,,Estimation of fraction absorbed (Fa) in the human intestine using biosensor technology.,Other,10841786.0,
93,29925,5,2,,103164453,2119,Unspecified,,,,,Volume of distribution in man (IV dose),Other,12061889.0,
94,40539,3,7,,103164453,2119,Active,,,,,Selectivity for beta-1 receptor,Other,2903243.0,
95,40689,7,1,,103164453,2119,Active,,,0.00298,IC50,Compound was tested for inhibition of [3H]dihydroalprenolol radioligand binding to Beta-2 adrenergic receptor in calf lung membranes.,Confirmatory,6126588.0,
96,40693,3,8,,103164453,2119,Unspecified,,,,,Ratio between the IC50 values of beta-2 of calf lung and beta-1 receptor of dog heart,Other,6126588.0,
97,41488,3,7,,103164453,2119,Active,,,,,Selectivity for beta-2 adrenergic receptor,Other,2903243.0,
98,41620,5,1,,103164453,2119,Unspecified,,,,,Binding affinity towards rat beta adrenergic receptor from heart membranes.,Other,6131128.0,
99,41621,5,1,,103164453,2119,Unspecified,,,,,Binding affinity towards rat beta adrenergic receptor from lung membranes.,Other,6131128.0,
100,41763,3,7,,103164453,2119,Unspecified,,,,,"% specific binding blocked by the compound fraction of (1x10E-5) in beta adrenergic receptor from heart membranes, after serial wash",Other,6131128.0,
101,41764,3,7,,103164453,2119,Unspecified,,,,,"% specific binding blocked by the compound fraction of (1x10E-5) in beta adrenergic receptor from lung membranes, after serial wash",Other,6131128.0,
102,41885,9,2,,103164453,2119,Active,,,0.0023,IC50,Compound was evaluated for its Beta adrenergic receptor blocking action,Confirmatory,11459642.0,
103,41891,3,6,,103164453,2119,Active,,,,,Tested for intrinsic sympathomimetic activity (ISA); antagonist with partial agonistic properties,Other,2903243.0,
104,41895,3,7,,103164453,2119,Unspecified,,,,,Beta-blocking activity was measured by applying the stepwise linear discriminate analysis; Active,Other,,
105,42029,7,2,,103164453,2119,Active,,,0.00488,IC50,Compound was tested for inhibition of [3H]dihydroalprenolol radioligand binding to Beta-1 adrenergic receptor in dog heart.,Confirmatory,6126588.0,
106,47221,8,2,,103164453,2119,Inconclusive,,,,,Compound was evaluated for its antifungal activity against Candida albicans CY1002; Not tested,Other,11459642.0,
107,78477,3,4,,103164453,2119,Unspecified,,,,,Ability to bind to guinea pig atrial homogenate,Other,7381857.0,
108,91480,3,8,,103164453,2119,Unspecified,,,,,Ability to bind to human serum albumin (HSA),Other,7381857.0,
109,91481,4,7,,103164453,2119,Unspecified,,,,,Binding constant against human serum albumin (HSA),Other,11728183.0,
110,143929,8,4,,103164453,2119,Inconclusive,,,,,Compound was evaluated for its inhibitory activity against Candida albicans N-myristoyltransferase (CaNmt); Not tested,Other,11459642.0,
111,144060,8,4,,103164453,2119,Inconclusive,,,,,Compound was evaluated for its inhibitory activity against human N-myristoyltransferase (HsNmt); Not tested,Other,11459642.0,
112,156202,3,4,,103164453,2119,Unspecified,,,,,Binding to POPC (palmitoyl-oleolyl-phosphatidyl-choline) liposomes using biosensor system,Other,10841786.0,
113,156204,3,4,,103164453,2119,Unspecified,,,,,Binding to POPC/GMI liposomes using biosensor system,Other,10841786.0,
114,165515,3,3,,103164453,2119,Unspecified,,,,,Average IOP after administration was determined,Other,7783133.0,
115,167762,3,3,,103164453,2119,Active,,,,,Compound was tested for decrease in IOP for 2-3 h (in vivo); Significant reduction was observed,Other,7783133.0,
116,204831,9,1,,103164453,2119,Active,,,4.2,IC50,Inhibition of rat microsomal squalene synthase,Confirmatory,7473541.0,
117,211858,5,3,,103164453,2119,Inconclusive,,,,,Compound was tested for its toxicity after intravenous administration to mice in experiment 1; No data,Other,,
118,211860,5,3,,103164453,2119,Inconclusive,,,,,Compound was tested for its toxicity after intravenous administration to mice in experiment 2; No data,Other,,
119,211863,6,3,,103164453,2119,Unspecified,,,,,Compound was tested for its toxicity after oral administration to mice in experiment 1,Other,,
120,211865,6,3,,103164453,2119,Unspecified,,,,,Compound was tested for its toxicity after oral administration to mice in experiment 2,Other,,
121,218845,3,7,,103164453,2119,Unspecified,,,,,Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the membranes of bovine skeletal muscle preparation,Other,2836587.0,
122,218848,4,6,,103164453,2119,Unspecified,,,,,Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the Chang living cells,Other,2836587.0,
123,227718,7,1,,103164453,2119,Unspecified,,,,,Binding energy by using the equation deltaG obsd = -RT ln KD,Other,6094812.0,
124,231333,3,3,,103164453,2119,Unspecified,,,,,Ratio of [(apical to basal)/(basal to apical)] (Caco-2 cell monolayer),Other,11384238.0,
125,236268,3,4,,103164453,2119,Unspecified,,,,,Fraction absorbed in human intestine after oral administration compound was measured,Other,15658873.0,
126,236912,6,1,,103164453,2119,Unspecified,,,,,Permeability Coefficient in 2/4/A1 cell model,Other,15658873.0,
127,236913,6,1,,103164453,2119,Unspecified,,,,,Permeability Coefficient in Caco-2 cell culture model,Other,15658873.0,
128,236914,6,1,,103164453,2119,Unspecified,,,,,Permeability Coefficient in hexadecane membranes model,Other,15658873.0,
129,236916,6,1,,103164453,2119,Unspecified,,,,,Percentage of mass balance in hexadecane membranes model,Other,15658873.0,
130,237585,5,2,,103164453,2119,Unspecified,,,,,Tested for fraction of oral dose absorbed orally in humans,Other,15857133.0,
131,237685,4,3,,103164453,2119,Unspecified,,,,,Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system,Other,15857133.0,
132,288184,9,1,,103164453,2119,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA,Other,17418579.0,
133,288185,7,1,,103164453,2119,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of stirred water layer,Other,17418579.0,
134,288192,3,4,,103164453,2119,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,17418579.0,
135,288193,3,4,,103164453,2119,Unspecified,,,,,"Flux ionization constant, pKa of the membrane permeability coefficient of the compound",Other,17418579.0,
136,288194,3,5,,103164453,2119,Unspecified,,,,,"Intrinsic artificial membrane permeability coefficient, log P0 of the compound",Other,17418579.0,
137,312895,3,4,,103164453,2119,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,18189348.0,
138,312896,3,4,,103164453,2119,Unspecified,,,,,"Partition coefficient, log P by UPLC method",Other,18189348.0,
139,350216,3,3,,103164453,2119,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,19397318.0,
140,350217,3,3,,103164453,2119,Unspecified,,,,,"Octanol-water partition coefficient, log Pn of the compound",Other,19397318.0,
141,350218,3,4,,103164453,2119,Unspecified,,,,,"Octanol-water partition coefficient, log PC of the compound",Other,19397318.0,
142,350219,3,4,,103164453,2119,Unspecified,,,,,"Lipophilicity, log K at pH 2 by by hydrophilic interaction chromatography using 95% acetonitrile as mobile phase",Other,19397318.0,
143,350220,3,4,,103164453,2119,Unspecified,,,,,"Lipophilicity, log K at pH 2 by by hydrophilic interaction chromatography using 100% water as mobile phase",Other,19397318.0,
144,384955,4,4,,103164453,2119,Unspecified,,,,,Intrinsic aqueous solubility at pH 10 by shake-flask method,Other,18396854.0,
145,395325,3,3,,103164453,2119,Unspecified,,,,,"Lipophilicity, log P by microemulsion electrokinetic chromatography",Other,19256501.0,
146,395328,3,3,,103164453,2119,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,19256501.0,
147,425652,7,2,,103164453,2119,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
148,425653,7,2,,103164453,2119,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
149,434959,1,1,,85788463,2119,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
150,444050,7,1,,103164453,2119,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
151,444051,6,2,,103164453,2119,Unspecified,,,,,Total clearance in human,Other,20070106.0,
152,444052,6,2,,103164453,2119,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
153,444053,6,2,,103164453,2119,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
154,444054,6,1,,103164453,2119,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
155,444055,3,3,,103164453,2119,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
156,444056,3,3,,103164453,2119,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
157,444057,3,3,,103164453,2119,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
158,444058,6,2,,103164453,2119,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
159,455986,3,5,,103164453,2119,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
160,463106,1,2,,90340777,2119,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
161,476929,3,3,,103164453,2119,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
162,485290,1,1,,26752306,2119,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
163,485290,1,1,,50105226,2119,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
164,485295,1,2,,90340777,2119,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
165,485297,1,1,,90340777,2119,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
166,485298,1,1,,90340777,2119,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
167,485313,1,2,,90340777,2119,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
168,485342,1,2,,90340777,2119,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
169,485345,1,2,,90340777,2119,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
170,485366,1,2,,90340777,2119,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
171,485368,1,2,,90340777,2119,Inconclusive,72386991.0,3656265.0,,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
172,488772,1,1,,90340777,2119,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
173,488773,1,2,,90340777,2119,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
174,488816,1,1,,90340777,2119,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
175,488837,1,1,,90340777,2119,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
176,488949,1,2,,90340777,2119,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
177,488953,1,1,,90340777,2119,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
178,488978,1,1,,90340777,2119,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
179,488981,1,1,,90340777,2119,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
180,488982,1,1,,90340777,2119,Inactive,4503383.0,1812.0,0.6513,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
181,488983,1,1,,90340777,2119,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
182,493106,1,1,,90340777,2119,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
183,493107,1,1,,90340777,2119,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
184,493153,1,1,,90340777,2119,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
185,493153,1,1,,90340777,2119,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
186,493164,1,2,,90340777,2119,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
187,493164,1,2,,90340777,2119,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
188,493164,1,2,,90340777,2119,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
189,504327,1,1,,90340777,2119,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
190,504332,1,1,,90340777,2119,Inconclusive,168985070.0,,8.9125,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
191,504536,1,1,,90340777,2119,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
192,504547,1,1,,90340777,2119,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
193,504548,1,2,,90340777,2119,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
194,504749,1,3,,26752306,2119,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
195,504749,1,3,,104171111,2119,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
196,504749,1,3,1.0,26752306,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
197,504749,1,3,2.0,104171111,2119,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
198,504749,1,3,3.0,104171111,2119,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
199,504749,1,3,4.0,26752306,2119,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
200,504749,1,3,5.0,104171111,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
201,504749,1,3,6.0,26752306,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
202,504749,1,3,7.0,26752306,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
203,504749,1,3,8.0,26752306,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
204,504749,1,3,9.0,104171111,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
205,504749,1,3,10.0,26752306,2119,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
206,504749,1,3,11.0,26752306,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
207,504749,1,3,12.0,104171111,2119,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
208,504749,1,3,13.0,26752306,2119,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
209,504749,1,3,14.0,104171111,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
210,504749,1,3,15.0,26752306,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
211,504749,1,3,16.0,26752306,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
212,504749,1,3,17.0,26752306,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
213,504749,1,3,18.0,26752306,2119,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
214,504749,1,3,19.0,26752306,2119,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
215,504749,1,3,20.0,104171111,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
216,504749,1,3,21.0,26752306,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
217,504749,1,3,22.0,104171111,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
218,504749,1,3,23.0,104171111,2119,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
219,504749,1,3,24.0,26752306,2119,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
220,504749,1,3,25.0,26752306,2119,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
221,504749,1,3,26.0,26752306,2119,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
222,504749,1,3,27.0,104171111,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
223,504749,1,3,28.0,104171111,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
224,504749,1,3,29.0,26752306,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
225,504749,1,3,30.0,104171111,2119,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
226,504749,1,3,31.0,104171111,2119,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
227,504749,1,3,32.0,26752306,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
228,504749,1,3,33.0,104171111,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
229,504749,1,3,34.0,26752306,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
230,504749,1,3,35.0,26752306,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
231,504749,1,3,36.0,104171111,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
232,504749,1,3,37.0,26752306,2119,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
233,504749,1,3,38.0,104171111,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
234,504749,1,3,39.0,26752306,2119,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
235,504749,1,3,40.0,26752306,2119,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
236,504749,1,3,41.0,104171111,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
237,504749,1,3,42.0,26752306,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
238,504749,1,3,43.0,26752306,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
239,504749,1,3,44.0,26752306,2119,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
240,504749,1,3,45.0,104171111,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
241,504749,1,3,46.0,26752306,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
242,504749,1,3,47.0,26752306,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
243,504749,1,3,48.0,26752306,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
244,504749,1,3,49.0,26752306,2119,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
245,504749,1,3,50.0,104171111,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
246,504749,1,3,51.0,26752306,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
247,504749,1,3,52.0,26752306,2119,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
248,504749,1,3,53.0,104171111,2119,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
249,504749,1,3,54.0,26752306,2119,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
250,504749,1,3,55.0,104171111,2119,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
251,504749,1,3,56.0,26752306,2119,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
252,504749,1,3,57.0,26752306,2119,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
253,504749,1,3,58.0,26752306,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
254,504749,1,3,59.0,104171111,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
255,504749,1,3,60.0,104171111,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
256,504749,1,3,61.0,26752306,2119,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
257,504810,1,2,,90340777,2119,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
258,504812,1,2,,90340777,2119,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
259,504832,1,1,,104171111,2119,Active,,,13.4591,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
260,504834,1,1,,104171111,2119,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
261,504836,1,2,,90340777,2119,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
262,504845,1,1,,90340777,2119,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
263,504845,1,1,,104171111,2119,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
264,504847,1,1,,90340777,2119,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
265,504847,1,1,,104171111,2119,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
266,504865,1,1,,90340777,2119,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
267,504865,1,1,,104171111,2119,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
268,513147,2,3,,103164453,2119,Inactive,,,,,Activity at human Beta-2 adrenergic receptor delta 5-C271+Trp135 mutant assessed as change in bimane fluorescence intensity by fluorescence spectroscopy,Other,16799554.0,
269,515780,5,1,,103164453,2119,Unspecified,,,,,Intrinsic solubility of the compound in water,Other,20810286.0,
270,540209,4,3,,103164453,2119,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
271,540210,4,3,,103164453,2119,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
272,540211,2,5,,103164453,2119,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
273,540212,4,3,,103164453,2119,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
274,540213,4,3,,103164453,2119,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
275,540256,1,2,,90340777,2119,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
276,540276,1,2,,26752306,2119,Inconclusive,420597.0,,25.929000000000002,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
277,540276,1,2,,50105225,2119,Inconclusive,420597.0,,25.929000000000002,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
278,540276,1,2,,50105226,2119,Inconclusive,420597.0,,25.929000000000002,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
279,540276,1,2,,90340777,2119,Inconclusive,420597.0,,29.081,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
280,567091,2,6,,103164453,2119,Unspecified,,,,,Drug absorption in human assessed as human intestinal absorption rate,Other,21112128.0,
281,588349,1,1,,90340777,2119,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
282,588378,1,1,,90340777,2119,Inconclusive,171543895.0,6311.0,31.6228,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
283,588453,1,1,,90340777,2119,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
284,588456,1,1,,90340777,2119,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
285,588579,1,1,,90340777,2119,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
286,588579,1,1,,104171111,2119,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
287,588579,1,1,,124879296,2119,Inconclusive,7705344.0,51426.0,33.5875,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
288,588795,1,1,,90340777,2119,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
289,588834,2,1,,26752306,2119,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
290,592681,1,4,,103164453,2119,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
291,598251,10,2,,103164453,2119,Inactive,238054374.0,5243.0,,IC50,Inhibition of human ABCB1-mediated rhodamine 123 efflux in mouse L5178 cells expressing human MDR1 after 20 mins by FACS analysis,Confirmatory,21341745.0,
292,598252,1,11,,103164453,2119,Unspecified,238054374.0,5243.0,,,Inhibition of human ABCB1-mediated rhodamine 123 efflux in mouse L5178 cells expressing human MDR1 at 0.1 mM after 20 mins by FACS analysis relative to 5 mM sodium orthovanadate,Other,21341745.0,
293,602332,1,1,,90340777,2119,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
294,602332,1,1,,104171111,2119,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
295,602332,1,1,,124879296,2119,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
296,604020,1,4,,103164453,2119,Active,,,,,Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
297,604021,3,1,,103164453,2119,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain measured per gram of brain tissue administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
298,604022,1,4,,103164453,2119,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
299,604023,1,3,,103164453,2119,Unspecified,,,,,Ratio of total drug level in brain to plasma in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
300,604024,1,3,,103164453,2119,Unspecified,,,,,Unbound brain to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr,Other,19764786.0,
301,604025,1,4,,103164453,2119,Unspecified,,,,,Unbound CSF to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
302,620386,4,5,,103164453,2119,Active,48429211.0,153.0,0.01122,Kd,Displacement of [3H]-CGP 12177 from human beta-1 adrenergic receptor expressed in CHOK1 cells,Confirmatory,21870877.0,
303,620387,4,5,,103164453,2119,Active,296439450.0,154.0,0.0005009999999999999,Kd,Displacement of [3H]-CGP 12177 from human beta-2 adrenergic receptor expressed in CHOK1 cells,Confirmatory,21870877.0,
304,620388,4,5,,103164453,2119,Active,461604.0,155.0,0.13804,Kd,Displacement of [3H]-CGP 12177 from human beta-3 adrenergic receptor expressed in CHOK1 cells,Confirmatory,21870877.0,
305,620389,2,6,,103164453,2119,Active,48429211.0,153.0,0.00427,Kd,Antagonist activity at human beta-1 adrenergic receptor site 1 expressed in cimeterol-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,Confirmatory,21870877.0,
306,620390,2,6,,103164453,2119,Active,48429211.0,153.0,0.17783,Kd,Antagonist activity at human beta-1 adrenergic receptor site 1 expressed in CGP 12177-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,Confirmatory,21870877.0,
307,620391,2,6,,103164453,2119,Active,296439450.0,154.0,0.000295,Kd,Antagonist activity at human beta-2 adrenergic receptor expressed in salbutamol-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,Confirmatory,21870877.0,
308,620392,2,6,,103164453,2119,Active,461604.0,155.0,0.07586,Kd,Antagonist activity at human beta-3 adrenergic receptor expressed in fenoterol-stimulated CHOK1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,Confirmatory,21870877.0,
309,620393,1,9,,103164453,2119,Unspecified,48429211.0,153.0,,,Partial agonist activity at human beta-1 adrenergic receptor expressed in CHOK1 cells assessed as CRE-SPAP production at 1 uM by fluorescence correlation spectroscopic analysis relative to 10 uM isoprenaline,Other,21870877.0,
310,620394,1,9,,103164453,2119,Unspecified,296439450.0,154.0,,,Partial agonist activity at human beta-2 adrenergic receptor expressed in CHOK1 cells assessed as CRE-SPAP production at 1 uM by fluorescence correlation spectroscopic analysis relative to 10 uM isoprenaline,Other,21870877.0,
311,620395,1,9,,103164453,2119,Unspecified,461604.0,155.0,,,Partial agonist activity at human beta-3 adrenergic receptor expressed in CHOK1 cells assessed as CRE-SPAP production at 1 uM by fluorescence correlation spectroscopic analysis relative to 10 uM isoprenaline,Other,21870877.0,
312,624030,1,2,,104171111,2119,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
313,624031,1,2,,104171111,2119,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
314,624032,1,2,,104171111,2119,Inactive,8393992.0,24660.0,25.5748,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
315,624044,1,2,,104171111,2119,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
316,624101,1,2,,85788463,2119,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
317,624146,1,1,,90340777,2119,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
318,624147,1,1,,90340777,2119,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
319,624148,1,2,,90340777,2119,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
320,624149,1,1,,90340777,2119,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
321,624156,1,1,,85788463,2119,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
322,624170,1,1,,104171111,2119,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
323,624172,1,1,,104171111,2119,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
324,624173,1,3,,104171111,2119,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
325,624296,1,1,,26752306,2119,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
326,624296,1,1,,104171111,2119,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
327,624297,1,1,,26752306,2119,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
328,624297,1,1,,104171111,2119,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
329,624349,1,2,,92308802,2119,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
330,624455,1,1,,90340777,2119,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
331,651631,4,1,,144203635,2119,Inconclusive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
332,651632,4,1,,144203635,2119,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
333,651633,4,1,,144203635,2119,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
334,651634,4,1,,144203635,2119,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
335,651635,1,3,,90340777,2119,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
336,651828,1,2,,92308802,2119,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
337,652048,1,2,,144203635,2119,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
338,652051,1,1,,144203635,2119,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
339,652106,1,1,,90340777,2119,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
340,669781,1,8,,103164453,2119,Unspecified,238054374.0,5243.0,,,Inhibition of human recombinant MDR1 expressed in mouse L5178Y cells assessed as inhibition of rhodamine-123 efflux at 10'-4 M preincubated for 10 mins measured after 20 mins by FACS analysis,Other,24900460.0,
341,686977,2,1,,49698847,2119,Inconclusive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
342,686978,1,1,,144203635,2119,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
343,686979,1,1,,144203635,2119,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
344,720516,2,1,,144203635,2119,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
345,720532,1,1,,124879296,2119,Inconclusive,420597.0,,12.5893,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
346,720532,1,1,,144203635,2119,Inconclusive,420597.0,,28.1838,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
347,720533,1,1,,124879296,2119,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
348,720533,1,1,,144203635,2119,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
349,720538,1,2,,90340777,2119,Inconclusive,220983390.0,410.0,0.0054,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
350,720552,2,1,,144203635,2119,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
351,720559,1,2,,90340777,2119,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
352,720572,1,2,,90340777,2119,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
353,720573,1,2,,90340777,2119,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
354,720634,2,1,,144203635,2119,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
355,720635,2,1,,144203635,2119,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
356,720637,2,1,,144203635,2119,Inconclusive,,,18.1246,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
357,720641,1,2,,92308802,2119,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
358,720674,2,2,,144203635,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
359,720675,2,2,,144203635,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
360,720678,2,1,,144203635,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
361,720679,2,1,,144203635,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
362,720680,2,1,,144203635,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
363,720681,2,1,,144203635,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
364,720682,2,1,,144203635,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
365,720683,2,1,,144203635,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
366,720684,2,1,,144203635,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
367,720685,2,1,,144203635,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
368,720686,2,1,,144203635,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
369,720687,2,2,,144203635,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
370,720691,4,1,,144203635,2119,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
371,720692,3,1,,144203635,2119,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
372,720693,3,1,,144203635,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
373,720717,1,3,,92308802,2119,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
374,720719,2,1,,144203635,2119,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
375,720725,2,1,,144203635,2119,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
376,743012,3,1,,144203635,2119,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
377,743014,3,1,,144203635,2119,Inconclusive,,,11.8832,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
378,743015,3,1,,144203635,2119,Inconclusive,,,21.1317,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
379,743033,3,1,,144203635,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
380,743035,2,1,,144203635,2119,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
381,743036,2,1,,144203635,2119,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
382,743040,3,1,,144203635,2119,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
383,743041,3,1,,144203635,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
384,743042,3,1,,144203635,2119,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
385,743053,2,1,,144203635,2119,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
386,743054,2,1,,144203635,2119,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
387,743063,2,1,,144203635,2119,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
388,743064,3,1,,144203635,2119,Inconclusive,,,18.8336,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
389,743065,3,1,,144203635,2119,Inconclusive,399498506.0,24831.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
390,743066,3,1,,144203635,2119,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
391,743067,2,1,,144203635,2119,Inconclusive,399498506.0,24831.0,33.4915,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
392,743069,2,1,,144203635,2119,Inactive,348019627.0,2099.0,0.0477,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
393,743074,2,1,,144203635,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
394,743075,2,1,,144203635,2119,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
395,743077,2,1,,144203635,2119,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
396,743078,2,1,,144203635,2119,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
397,743079,3,1,,144203635,2119,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
398,743080,3,1,,144203635,2119,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
399,743081,3,1,,144203635,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
400,743083,3,1,,144203635,2119,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
401,743084,3,1,,144203635,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
402,743085,3,1,,144203635,2119,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
403,743086,3,1,,144203635,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
404,743091,2,1,,144203635,2119,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
405,743094,3,1,,144203635,2119,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
406,743122,2,1,,144203635,2119,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
407,743139,2,1,,144203635,2119,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
408,743140,2,1,,144203635,2119,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
409,743191,3,1,,170465812,2119,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
410,743194,3,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
411,743199,2,1,,170465812,2119,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
412,743202,4,1,,170465812,2119,Inconclusive,20149576.0,4780.0,26.6011,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
413,743203,3,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
414,743205,1,1,,90340777,2119,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
415,743205,1,1,,90340777,2119,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
416,743206,1,1,,90340777,2119,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
417,743206,1,1,,90340777,2119,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
418,743207,1,1,,90340777,2119,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
419,743207,1,1,,90340777,2119,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
420,743209,3,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
421,743210,4,1,,170465812,2119,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
422,743211,3,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
423,743212,3,1,,170465812,2119,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
424,743213,3,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
425,743215,3,1,,170465812,2119,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
426,743217,3,1,,170465812,2119,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
427,743218,3,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
428,743219,3,1,,170465812,2119,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
429,743220,3,1,,170465812,2119,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
430,743221,3,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
431,743222,3,1,,170465812,2119,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
432,743223,3,1,,170465812,2119,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
433,743224,3,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
434,743225,3,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
435,743226,2,1,,170465812,2119,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
436,743227,2,1,,170465812,2119,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
437,743228,3,1,,170465812,2119,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
438,743239,2,1,,170465812,2119,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
439,743240,2,1,,170465812,2119,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
440,743241,2,1,,170465812,2119,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
441,743242,2,1,,170465812,2119,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
442,743244,1,1,,90340777,2119,Inconclusive,,,1.122,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
443,743244,1,1,,144203635,2119,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
444,777625,3,2,,103164453,2119,Active,296439450.0,154.0,0.001,Ki,Displacement of [3H]-CGP12177 from human recombinant beta2 adrenoceptor expressed in CHOK1 cells after 1.5 hrs by scintillation counting analysis,Confirmatory,24454993.0,
445,777628,4,2,,103164453,2119,Unspecified,296439450.0,154.0,,Kd,Binding affinity to N-terminal FLAG-tagged C-terminal His-10-tagged human beta2 adrenoceptor expressed in insect Sf9 cells by surface plasmon resonance analysis,Confirmatory,24454993.0,
446,781326,1,2,,103164453,2119,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X,Other,24249037.0,
447,781328,1,2,,103164453,2119,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 2005,Other,24249037.0,
448,977599,1,1,,103164453,2119,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
449,977602,1,2,,103164453,2119,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
450,1091955,1,2,,103164453,2119,Unspecified,,,,,"Dissociation constant, pKa of the compound at pH 7.3",Other,20879794.0,
451,1091956,1,1,,103164453,2119,Unspecified,,,,,"Apparent hydrophobicity, log D of the compound in Octanol-buffer",Other,20879794.0,
452,1091957,1,1,,103164453,2119,Unspecified,,,,,Apparent permeability of the compound by PAMPA,Other,20879794.0,
453,1091958,2,1,,103164453,2119,Unspecified,,,,,"Hydrophobicity, log P of the compound in octanol-water by shaking-flask method",Other,20879794.0,
454,1117298,1,2,,170465812,2119,Inactive,,,22.3872,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
455,1117304,1,2,,170465812,2119,Active,,,28.1838,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
456,1117305,1,2,,170465812,2119,Active,,,25.1189,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
457,1117310,1,1,,170465812,2119,Inactive,,,22.3872,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
458,1117312,1,1,,170465812,2119,Active,,,25.1189,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
459,1117314,1,1,,170465812,2119,Inactive,,,28.1838,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
460,1117326,1,1,,170465812,2119,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
461,1117329,1,1,,170465812,2119,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
462,1117336,1,1,,170465812,2119,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
463,1117340,1,1,,170465812,2119,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
464,1117341,1,1,,170465812,2119,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
465,1117342,1,1,,170465812,2119,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
466,1117343,1,1,,170465812,2119,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
467,1117346,1,1,,170465812,2119,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
468,1123536,1,3,,103164453,2119,Active,114754.0,24925.0,,,Displacement of [3H]DHA from beta1 adrenergic receptor in rat ventricular muscle by competitive binding assay,Other,37339.0,
469,1123537,1,3,,103164453,2119,Active,114768.0,24176.0,,,Displacement of [3H]DHA from beta2 adrenergic receptor in rat lung muscle by competitive binding assay,Other,37339.0,
470,1123538,1,1,,103164453,2119,Unspecified,,,,,Cardio selectivity ratio of Kapp for beta2 adrenergic receptor in rat lung muscle to Kapp for beta1 adrenergic receptor in rat ventricular muscle,Other,37339.0,
471,1129361,1,1,,103164453,2119,Unspecified,,,,,Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis,Other,24601604.0,
472,1159387,1,2,,103164453,2119,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
473,1159395,1,2,,103164453,2119,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in rat hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736",Other,,
474,1159396,1,2,,103164453,2119,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
475,1159509,1,1,,170465812,2119,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
476,1159515,1,1,,170465812,2119,Inconclusive,,,10.6822,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
477,1159516,1,1,,170465812,2119,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
478,1159517,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
479,1159518,1,1,,170465812,2119,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
480,1159519,1,1,,170465812,2119,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
481,1159520,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
482,1159521,1,1,,170465812,2119,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
483,1159523,1,1,,170465812,2119,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
484,1159524,1,1,,124879296,2119,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
485,1159525,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
486,1159526,1,1,,170465812,2119,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
487,1159527,1,1,,170465812,2119,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
488,1159528,1,1,,170465812,2119,Inconclusive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
489,1159529,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
490,1159531,1,1,,170465812,2119,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
491,1159551,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
492,1159552,1,1,,170465812,2119,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
493,1159553,2,1,,170465812,2119,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
494,1159555,1,1,,170465812,2119,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
495,1159580,2,1,,268735354,2119,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
496,1159580,2,1,,273002719,2119,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
497,1159607,2,1,,312596766,2119,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
498,1159614,1,2,,170465812,2119,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
499,1209581,1,2,,103164453,2119,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis,Other,21149540.0,
500,1209582,1,1,,103164453,2119,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs,Other,21149540.0,
501,1209583,1,1,,103164453,2119,Unspecified,,,,,"Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma",Other,21149540.0,
502,1209593,1,1,,103164453,2119,Unspecified,,,,,"Dissociation constant, pKa of the acidic compound by capillary electrophoresis-mass spectrometry analysis",Other,21149540.0,
503,1210069,1,2,,103164453,2119,Unspecified,21264413.0,1573.0,50.0,IC50,Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method,Confirmatory,23033255.0,
504,1211791,1,1,,103164453,2119,Unspecified,,,,,Fraction unbound in human hepatocytes,Other,21998403.0,
505,1211792,1,1,,103164453,2119,Unspecified,,,,,Hepatic clearance in human,Other,21998403.0,
506,1211793,1,1,,103164453,2119,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,21998403.0,
507,1211794,1,2,,103164453,2119,Unspecified,,,,,Fraction unbound in blood (not specified),Other,21998403.0,
508,1211795,1,1,,103164453,2119,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,21998403.0,
509,1211796,1,1,,103164453,2119,Unspecified,,,,,Intrinsic clearance in cryopreserved human HepaRG cells assessed per 10'6 cells by LC-MS/MS method,Other,21998403.0,
510,1211797,1,1,,103164453,2119,Unspecified,,,,,Intrinsic clearance in cryopreserved human hepatocytes cells assessed per 10'6 cells by LC-MS/MS method,Other,21998403.0,
511,1211798,1,1,,103164453,2119,Unspecified,,,,,Intrinsic clearance in human using well stirred liver model by LC-MS/MS method,Other,21998403.0,
512,1223488,1,1,,103164453,2119,Unspecified,,,,,"1-Octanol-water distribution coefficient, log D of the compound at pH 7.4",Other,22096083.0,
513,1223489,1,1,,103164453,2119,Unspecified,,,,,"1-Octanol-water distribution coefficient, log D of the compound at pH 7.4 by shake flask method",Other,22096083.0,
514,1223490,1,1,,103164453,2119,Unspecified,,,,,Apparent permeability across human differentiated Caco2 cells,Other,22096083.0,
515,1223491,1,1,,103164453,2119,Unspecified,,,,,Apparent permeability across human differentiated Caco2 cells at 500 uM after 1 hr by HPLC-DAD analysis,Other,22096083.0,
516,1224834,3,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
517,1224835,1,1,,170465812,2119,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
518,1224836,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
519,1224837,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
520,1224838,1,1,,170465812,2119,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
521,1224839,1,1,,170465812,2119,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
522,1224840,3,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
523,1224841,3,1,,170465812,2119,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
524,1224842,3,1,,170465812,2119,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
525,1224843,1,1,,170465812,2119,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
526,1224844,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
527,1224845,1,1,,170465812,2119,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
528,1224846,1,1,,170465812,2119,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
529,1224847,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
530,1224848,3,1,,170465812,2119,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
531,1224849,3,1,,170465812,2119,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
532,1224857,2,1,,170465812,2119,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
533,1224859,2,1,,90340777,2119,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
534,1224859,2,1,,170465812,2119,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
535,1224863,1,1,,176484037,2119,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
536,1224863,1,1,,316919573,2119,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
537,1224867,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
538,1224868,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
539,1224869,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
540,1224870,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
541,1224871,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
542,1224872,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
543,1224873,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
544,1224874,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
545,1224875,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
546,1224876,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
547,1224877,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
548,1224878,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
549,1224879,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
550,1224880,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
551,1224881,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
552,1224882,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
553,1224883,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
554,1224884,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
555,1224885,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
556,1224886,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
557,1224887,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
558,1224888,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
559,1224889,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
560,1224890,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
561,1224892,1,1,,170465812,2119,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
562,1224893,1,1,,170465812,2119,Inconclusive,66775687.0,9970.0,29.8493,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
563,1224894,1,1,,170465812,2119,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
564,1224895,1,1,,170465812,2119,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
565,1224896,1,1,,170465812,2119,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
566,1224905,2,1,,92308802,2119,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
567,1224905,2,1,,92308802,2119,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
568,1259241,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
569,1259242,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
570,1259243,1,1,,170465812,2119,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
571,1259244,1,1,,170465812,2119,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
572,1259247,1,1,,170465812,2119,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
573,1259248,1,1,,170465812,2119,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
574,1259344,1,1,,144203635,2119,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
575,1259355,1,1,,26752306,2119,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
576,1259356,1,1,,144203635,2119,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
577,1259364,1,1,,170465812,2119,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
578,1259365,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
579,1259366,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
580,1259367,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
581,1259368,1,1,,170465812,2119,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
582,1259369,1,1,,170465812,2119,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
583,1259377,1,1,,170465812,2119,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
584,1259378,1,1,,170465812,2119,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
585,1259379,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
586,1259380,1,1,,170465812,2119,Inconclusive,,,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
587,1259381,1,1,,170465812,2119,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
588,1259382,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
589,1259383,1,1,,170465812,2119,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
590,1259384,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
591,1259385,1,1,,170465812,2119,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
592,1259386,1,1,,170465812,2119,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
593,1259387,1,1,,170465812,2119,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
594,1259388,1,1,,170465812,2119,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
595,1259390,1,1,,170465812,2119,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
596,1259391,1,1,,170465812,2119,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
597,1259392,1,1,,170465812,2119,Inconclusive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
598,1259393,1,1,,170465812,2119,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
599,1259394,1,1,,170465812,2119,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
600,1259395,1,1,,170465812,2119,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
601,1259396,1,1,,170465812,2119,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
602,1259400,1,1,,170465812,2119,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
603,1259401,1,1,,170465812,2119,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
604,1259402,1,1,,170465812,2119,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
605,1259403,1,1,,170465812,2119,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
606,1259404,1,1,,170465812,2119,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
607,1259416,1,2,,340079469,2119,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
608,1259416,1,2,,375174818,2119,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
609,1259421,1,1,,340079469,2119,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
610,1259421,1,1,,375174818,2119,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
611,1259423,1,2,,354771989,2119,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
612,1259423,1,2,,354790887,2119,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
613,1259423,1,2,,354949143,2119,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
